Novo Nordisk’s next-generation weight-loss candidate CagriSema — a fixed-ratio combination of semaglutide and the amylin analog cagrilintide — failed to demonstrate superiority or even non-inferiority to Eli Lilly’s tirzepatide (Zepbound) in a Phase 3 head-to-head trial. Novo Nordisk shares fell more than 13% on the news.

CagriSema was supposed to be Novo’s answer to Lilly’s dominance. The combination therapy added an amylin pathway to semaglutide’s GLP-1 mechanism, theoretically producing greater weight loss than either component alone. Earlier data had been promising enough to justify a direct comparison trial against the market’s most effective drug.

The trial did not deliver. While specific efficacy numbers are subject to the full data publication, the topline result was unambiguous: CagriSema did not outperform tirzepatide on the primary endpoint.

This result reshapes the competitive narrative in obesity therapeutics. For the past two years, the story was a Lilly-Novo duopoly — two pharmaceutical giants splitting a market projected to reach $100 billion annually. That framing is now under pressure. Analysts are describing a shift from “duopoly” to “Lilly leadership.”

The implications extend beyond one trial. Novo Nordisk issued guidance warning of a potential 13% drop in sales, while Lilly raised its 2026 revenue targets to record levels. Meanwhile, smaller companies are positioning for the space that CagriSema’s stumble has opened. Viking Therapeutics (VK2735) and Amgen (MariTide) are advancing next-generation candidates that could compete for second position.

For patients and clinicians, the practical takeaway is simpler: tirzepatide remains the efficacy benchmark, and nothing in the current pipeline has beaten it head-to-head.